Essex Bio-Technology FY26 H1 profit drops 32.2% to HK$ 110.72 million; revenue falls 10.5% to HK$ 784.69 million

• Essex Bio-Technology posted profit of HK$ 110.72 million for the six months ended June 30, down 32.2%.
• Turnover fell 10.5% to HK$ 784.69 million; basic and diluted EPS dropped to HK19.53 cents from HK28.82 cents.
• Net profit margin narrowed 4.5 percentage points to 14.1%; gross margin slipped 5.2 percentage points to 83.6%.
• Interim dividend set at HK5 cents per share, down from HK7 cents; cash and cash equivalents rose to HK$ 806.63 million.
• SkQ1 dry-eye asset transfer work continued; anti-VEGF HLX04-O wet-AMD program advanced after AURA-2 met its primary endpoint in June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Essex Bio-Technology Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260805-12273900), on August 05, 2026, and is solely responsible for the information contained therein.